Core Message - Amarin Corporation emphasizes the urgent need to utilize existing, proven therapies to significantly reduce cardiovascular disease (CVD) events in the U.S. during American Heart Month [1][7]. Group 1: Current State of Cardiovascular Disease - CVD remains the leading cause of death in the U.S., affecting nearly half of the adult population, with 130.6 million adults (48.9%) living with some form of CVD as of 2023 [2]. - Despite available treatments, millions of high-risk patients remain untreated or undertreated, highlighting a significant gap between evidence and practice [4][9]. Group 2: Available Therapies and Their Impact - Guideline-supported therapies such as statins, ezetimibe, PCSK9 inhibitors, and icosapent ethyl have a proven history of reducing cardiovascular events [3][5]. - High-risk patients often fail to achieve LDL-C targets, with cumulative CV event rates reaching approximately 40% over 10 years among those treated with statins [9]. Group 3: Call to Action - Amarin calls for the cardiovascular community to recommit to data-driven care, ensuring that patients receive evidence-based treatments that are already available [7][11]. - The company urges stakeholders to review current practices, reassess therapies that do not demonstrate event reduction, and refocus on therapies backed by rigorous outcomes data [10][11]. Group 4: Future Innovations - While future innovations in cardiovascular treatments are promising, they are years away from delivering proven clinical outcomes, making immediate implementation of existing therapies critical [5][6].

Core Insights - Amarin Corporation, in collaboration with HLS Therapeutics, will present scientific data on Icosapent Ethyl (IPE) at the Canadian Cardiovascular Congress (CCC) from October 23 to 26, 2025, emphasizing their commitment to advancing cardiovascular care [1][2] Group 1: Scientific Presentations - Data presented at CCC 2025 will highlight the clinical value of IPE for cardiometabolic conditions and explore the mechanistic effects of EPA on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist [2] - Featured abstracts include a poster presentation on the ENCORE study, which indicates that Icosapent Ethyl reduces cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome [2][3] - An oral presentation will discuss the effects of Icosapent Ethyl on the risk and duration of hospitalizations and death in the REDUCE-IT study [3] Group 2: Product Information - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising IPE, launched in the U.S. in January 2020 for high-risk patients with persistent cardiovascular risk despite statin therapy [7] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [7] - VASCEPA is approved and sold in multiple countries, including Canada, China, Australia, and various European nations under the brand name VAZKEPA [7]